JP6122871B2 - 多環式化合物誘導体、それらの製造方法および医薬用途 - Google Patents

多環式化合物誘導体、それらの製造方法および医薬用途 Download PDF

Info

Publication number
JP6122871B2
JP6122871B2 JP2014551505A JP2014551505A JP6122871B2 JP 6122871 B2 JP6122871 B2 JP 6122871B2 JP 2014551505 A JP2014551505 A JP 2014551505A JP 2014551505 A JP2014551505 A JP 2014551505A JP 6122871 B2 JP6122871 B2 JP 6122871B2
Authority
JP
Japan
Prior art keywords
formula
alkyl
heterocyclyl
cycloalkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503595A (ja
JP2015503595A5 (https=
Inventor
ヤン、ファンロン
ドン、チン
ハン、ジホェイ
ワン、チュァンフェイ
ジャン、リン
ワン、ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of JP2015503595A publication Critical patent/JP2015503595A/ja
Publication of JP2015503595A5 publication Critical patent/JP2015503595A5/ja
Application granted granted Critical
Publication of JP6122871B2 publication Critical patent/JP6122871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014551505A 2012-01-12 2012-12-27 多環式化合物誘導体、それらの製造方法および医薬用途 Active JP6122871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210008286.9 2012-01-12
CN201210008286 2012-01-12
PCT/CN2012/087606 WO2013104257A1 (zh) 2012-01-12 2012-12-27 多环类衍生物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2015503595A JP2015503595A (ja) 2015-02-02
JP2015503595A5 JP2015503595A5 (https=) 2016-01-28
JP6122871B2 true JP6122871B2 (ja) 2017-04-26

Family

ID=48781054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551505A Active JP6122871B2 (ja) 2012-01-12 2012-12-27 多環式化合物誘導体、それらの製造方法および医薬用途

Country Status (14)

Country Link
US (1) US9139548B2 (https=)
EP (1) EP2803664B1 (https=)
JP (1) JP6122871B2 (https=)
KR (1) KR102036547B1 (https=)
CN (1) CN103429581B (https=)
AU (1) AU2012365706B2 (https=)
BR (1) BR112014016648B1 (https=)
CA (1) CA2860353A1 (https=)
MX (1) MX357780B (https=)
RU (1) RU2621039C1 (https=)
TW (1) TWI588136B (https=)
UA (1) UA115975C2 (https=)
WO (1) WO2013104257A1 (https=)
ZA (1) ZA201404625B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015062486A1 (en) * 2013-10-31 2015-05-07 Sunshine Lake Pharma Co., Ltd. Biphenyl compounds and uses thereof
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104788412B (zh) * 2014-01-22 2017-02-15 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
JP2017533981A (ja) 2014-10-14 2017-11-16 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 香料としてのヘキサデカ−８，１５−ジエナールの使用
CN106478616B (zh) * 2015-08-27 2020-05-12 江苏恒瑞医药股份有限公司 一种gpr40激动剂的结晶形式及其制备方法
CN108236611A (zh) * 2016-12-27 2018-07-03 江苏恒瑞医药股份有限公司 两种化合物联合在制备治疗糖尿病药物中的用途
CN108236609B (zh) * 2016-12-27 2022-10-21 江苏恒瑞医药股份有限公司 一种gpr40激动剂药物组合物及其制备方法
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100381584B1 (ko) * 1994-07-22 2003-08-21 알타나 파마 아게 디히드로벤조푸란
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
JP2007502815A (ja) 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ｐｐａｒ調節因子
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
BRPI0713378A8 (pt) * 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
NZ592603A (en) 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
SG173027A1 (en) 2009-01-30 2011-08-29 Toyama Chemical Co Ltd N-acyl anthranilic acid derivative or salt thereof
EP2423176A4 (en) * 2009-04-22 2012-11-07 Astellas Pharma Inc CARBOXYLIC ACID COMPOUND
WO2010143733A1 (en) * 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
CN102153553A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有氨基磺酰胺基氮杂环丁烷的口服碳青霉烯化合物
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof

Also Published As

Publication number Publication date
KR20140117498A (ko) 2014-10-07
CA2860353A1 (en) 2013-07-18
CN103429581A (zh) 2013-12-04
MX357780B (es) 2018-07-24
BR112014016648A8 (pt) 2017-07-04
AU2012365706B2 (en) 2015-08-20
HK1188781A1 (zh) 2014-05-16
EP2803664B1 (en) 2018-11-21
AU2012365706A1 (en) 2014-07-24
UA115975C2 (uk) 2018-01-25
EP2803664A4 (en) 2015-10-28
JP2015503595A (ja) 2015-02-02
US9139548B2 (en) 2015-09-22
TWI588136B (zh) 2017-06-21
CN103429581B (zh) 2015-08-26
WO2013104257A1 (zh) 2013-07-18
US20150005282A1 (en) 2015-01-01
TW201329058A (zh) 2013-07-16
KR102036547B1 (ko) 2019-10-25
RU2621039C1 (ru) 2017-05-31
ZA201404625B (en) 2015-11-25
MX2014008125A (es) 2014-09-22
BR112014016648B1 (pt) 2020-10-27
EP2803664A1 (en) 2014-11-19
BR112014016648A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
JP6122871B2 (ja) 多環式化合物誘導体、それらの製造方法および医薬用途
TWI617546B (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
EP2380881B1 (en) Novel bicyclic heterocyclic compound
BR112021014180A2 (pt) Composto, medicamento, método para ativar um receptor de orexina tipo 2 em um mamífero, método para profilaxia ou tratamento de narcolepsia em um mamífero, e, uso de um composto
JP2015503595A5 (https=)
KR102378648B1 (ko) 알도스테론 신타아제 억제제
EA028946B1 (ru) Способ получения соединений для применения в качестве ингибиторов sglt2
WO2008069242A1 (ja) 新規２環性複素環化合物
CN104418801A (zh) 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
CA2369695A1 (en) Agent for treating neuropathic pain
JP6615896B2 (ja) アルドステロン合成酵素阻害剤
CN103145663B (zh) (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
US20220162169A1 (en) 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine
TW202114989A (zh) 吡啶苯甲醯胺類衍生物、其製備方法及其在醫藥上的應用
HK1188781B (en) Polycyclic derivatives, preparation method and medical uses thereof
CN105566263A (zh) 一类新型含氮杂环衍生物、其制备方法及其作为药物的用途
WO2011065519A1 (ja) 置換オキソピペラジン化合物
CN119143734A (zh) 作为at2r拮抗剂的杂环化合物及其用途
BR112021001853A2 (pt) derivado de benzeno
JP2012246246A (ja) 置換オキソピペラジン化合物を含有する医薬組成物
HK1163676B (en) Bicyclic heterocyclic compound
HK1162504B (en) Novel bicyclic heterocyclic compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160627

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170403

R150 Certificate of patent or registration of utility model

Ref document number: 6122871

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250